Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia-Reference-Cited by-同舟云学术

Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia

Published:2016-07-30 Issue:35 Volume:7 Page:57036-57049
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Kang Min-Gu¹²,Choi Hyun-Woo¹,Lee Jun Hyung¹,Choi Yong Jun¹,Choi Hyun-Jung¹,Shin Jong-Hee¹,Suh Soon-Pal¹,Szardenings Michael³,Kim Hye-Ran⁴,Shin Myung-Geun¹²⁵

Affiliation:

1. Departments of Laboratory Medicine, Chonnam National University Medical School and Chonnam National University Hwasun Hospital, 322 Seoyang-ro, Hwasun-eup, Hwasun-gun, Jeollanam-do, South Korea

2. Brain Korea 21 Plus Project, Chonnam National University Medical School, Gwangju, South Korea

3. Department of Cell Therapy, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany

4. College of Korean Medicine, Dongshin University, Naju, Jeollanam-do, South Korea

5. Environmental Health Center for Childhood Leukemia and Cancer, Chonnam National University Medical School and Chonnam National University Hwasun Hospital, Hwasun-eup, Hwasun-gun, Jeollanam-do, South Korea

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Presence of triple positive driver mutations in JAK2, CALR and MPL in primary myelofibrosis: a case report and literature review;Hematology;2024-09-13

2. Germline genetic variants that predispose to myeloproliferative neoplasms and hereditary myeloproliferative phenotypes;Leukemia Research;2024-08

3. Prediction of acute coronary syndrome in patients with myeloproliferative neoplasms;Frontiers in Cardiovascular Medicine;2024-06-25

4. Treatment‐associated decline in JAK2V617F allele burden in polycythemia vera: What does it mean?;American Journal of Hematology;2024-05-20

5. A germline JAK2 exon12 mutation and a late somatic CALR mutation in a patient with essential thrombocythemia;Frontiers in Oncology;2024-01-04